EU allows use of UCB’s anti-epileptic Vimpat in children

The European Commission has ruled that UCB’s anti-epileptic Vimpat can be used in children.

Read on PharmaTimes

NICE nod for new Eylea indication

The National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for the treatment of visual impairment due to myopic chorodial neovascularisation.

Read on PharmaTimes

Sanofi’s Kevzara will be funded for NHS use

Some patients with rheumatoid arthritis living in England and Wales should get ‘routine’ NHS access to Sanofi’s Kevzara after cost regulators issued draft guidelines deeming the drug cost effective.

Read on PharmaTimes

FDA warning on Intercept’s Ocaliva after patient deaths

US regulators have issued a safety communication warning of the risk for serious liver injury and death from incorrect dosing of Intercept Pharmaceuticals' Ocaliva in patients with primary biliary cholangitis.

Read on PharmaTimes

Join us at the London Marriott Hotel, Grosvenor Square for the event of the year!

The Awards Ceremony for Marketer & Communications Team of the Year will take place at the London Marriott Hotel, Grosvenor Square on Thursday 9 November.

Read on PharmaTimes

1 2 3

Top of page

Industry News

The European Commission has ruled that UCB’s anti-epileptic Vimpat can be used in children.
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us